ReviewJournal of the National Cancer Institute2016
Cancer Prevention: Obstacles, Challenges and the Road Ahead.
Open access · bronzeAbstract readReview
In one paragraph
Review in Journal of the National Cancer Institute, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.
- Pooled it
- Development, Optimization, and Evaluation of Nano Self-Emulsifying Drug Delivery System Formulation Platform for Oral Bioavailability Enhancement of Sulfasalazine and Disulfiram in Lung Cancer Chemoprevention.Pharmaceutical research · 2026Article
- An Integrative Review of Computational Methods Applied to Biomarkers, Psychological Metrics, and Behavioral Signals for Early Cancer Risk Detection.Bioengineering (Basel, Switzerland) · 2025Article
- Cancer chemoprevention: signaling pathways and strategic approaches.Signal transduction and targeted therapy · 2025Review
- Potent prophylactic cancer vaccines harnessing surface antigens shared by tumour cells and induced pluripotent stem cells.Nature biomedical engineering · 2025Article
- A comprehensive analysis of the prognostic value, expression characteristics and immune correlation of MKI67 in cancers.Frontiers in immunology · 2025Article
- Advances in Preventive and Therapeutic Strategies for Oral Cancer: A Short Review.Journal of cancer prevention · 2024Review
- I trust doctors and midwives: exploring breast cancer literacy among women referring to the health centers in Iran.BMC cancer · 2024Article
- Cancer prevalence, incidence, and mortality rates in Afghanistan in 2020: A review study.Cancer reports (Hoboken, N.J.) · 2023Review
- ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023.JCO global oncology · 2023Article
- Worth a Pound of Cure? Emerging Strategies and Challenges in Cancer Immunoprevention.Cancer prevention research (Philadelphia, Pa.) · 2023Review
- Molecular disparities in colorectal cancers of White Americans, Alabama African Americans, and Oklahoma American Indians.NPJ precision oncology · 2023Article
- Geographic Characteristics of Various Cancers in Yogyakarta Province, Indonesia: A Spatial Analysis at the Community Level.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Antiangiogenic Phytochemicals Constituent of Diet as Promising Candidates for Chemoprevention of Cancer.Antioxidants (Basel, Switzerland) · 2022Review
- Angioprevention of Urologic Cancers by Plant-Derived Foods.Pharmaceutics · 2022Review
- Status of breast cancer screening strategies and indicators in Iran: A scoping review.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2022Article
- Metformin: review of epidemiology and mechanisms of action in pancreatic cancer.Cancer metastasis reviews · 2021Review
- Revisiting social MPE: an integration of molecular pathological epidemiology and social science in the new era of precision medicine.Expert review of molecular diagnostics · 2021Article
- Epigenetics/Epigenomics and Prevention of Early Stages of Cancer by Isothiocyanates.Cancer prevention research (Philadelphia, Pa.) · 2021Review
- Deep Learning Classifier with Patient's Metadata of Dermoscopic Images in Malignant Melanoma Detection.Journal of multidisciplinary healthcare · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Frank L MeyskensBiological Chemistry, Public Health, and Epidemiology, Chao Family Comprehensive Cancer Center, School of Medicine - University of California, Irvine, Irvine, CA (FLMJr); Arizona Board of Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences & BIO5, University of Arizona Cancer Center, Skin Cancer Institute, Tucson, AZ (DSA); Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention; Centre for Cancer Prevention, Queen Mary University of London, Mile End Road, London, UK (JC); Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA (TWK); Moores Cancer Center (SML) and Department of Family Medicine and Public Health, Cancer Prevention and Control Program (CLR), UC San Diego, San Diego, CA (SML); Dermatology Research Laboratories, University of Wisconsin; Madison, WI (HM); Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Center for Cancer Prevention Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ (CSY). flmeyske@uci.edu.
Hasan MukhtarBiological Chemistry, Public Health, and Epidemiology, Chao Family Comprehensive Cancer Center, School of Medicine - University of California, Irvine, Irvine, CA (FLMJr); Arizona Board of Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences & BIO5, University of Arizona Cancer Center, Skin Cancer Institute, Tucson, AZ (DSA); Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention; Centre for Cancer Prevention, Queen Mary University of London, Mile End Road, London, UK (JC); Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA (TWK); Moores Cancer Center (SML) and Department of Family Medicine and Public Health, Cancer Prevention and Control Program (CLR), UC San Diego, San Diego, CA (SML); Dermatology Research Laboratories, University of Wisconsin; Madison, WI (HM); Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Center for Cancer Prevention Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ (CSY).
Cheryl L RockBiological Chemistry, Public Health, and Epidemiology, Chao Family Comprehensive Cancer Center, School of Medicine - University of California, Irvine, Irvine, CA (FLMJr); Arizona Board of Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences & BIO5, University of Arizona Cancer Center, Skin Cancer Institute, Tucson, AZ (DSA); Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention; Centre for Cancer Prevention, Queen Mary University of London, Mile End Road, London, UK (JC); Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA (TWK); Moores Cancer Center (SML) and Department of Family Medicine and Public Health, Cancer Prevention and Control Program (CLR), UC San Diego, San Diego, CA (SML); Dermatology Research Laboratories, University of Wisconsin; Madison, WI (HM); Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Center for Cancer Prevention Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ (CSY).
Jack CuzickBiological Chemistry, Public Health, and Epidemiology, Chao Family Comprehensive Cancer Center, School of Medicine - University of California, Irvine, Irvine, CA (FLMJr); Arizona Board of Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences & BIO5, University of Arizona Cancer Center, Skin Cancer Institute, Tucson, AZ (DSA); Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention; Centre for Cancer Prevention, Queen Mary University of London, Mile End Road, London, UK (JC); Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA (TWK); Moores Cancer Center (SML) and Department of Family Medicine and Public Health, Cancer Prevention and Control Program (CLR), UC San Diego, San Diego, CA (SML); Dermatology Research Laboratories, University of Wisconsin; Madison, WI (HM); Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Center for Cancer Prevention Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ (CSY).
Thomas W KenslerBiological Chemistry, Public Health, and Epidemiology, Chao Family Comprehensive Cancer Center, School of Medicine - University of California, Irvine, Irvine, CA (FLMJr); Arizona Board of Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences & BIO5, University of Arizona Cancer Center, Skin Cancer Institute, Tucson, AZ (DSA); Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention; Centre for Cancer Prevention, Queen Mary University of London, Mile End Road, London, UK (JC); Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA (TWK); Moores Cancer Center (SML) and Department of Family Medicine and Public Health, Cancer Prevention and Control Program (CLR), UC San Diego, San Diego, CA (SML); Dermatology Research Laboratories, University of Wisconsin; Madison, WI (HM); Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Center for Cancer Prevention Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ (CSY).
Chung S YangBiological Chemistry, Public Health, and Epidemiology, Chao Family Comprehensive Cancer Center, School of Medicine - University of California, Irvine, Irvine, CA (FLMJr); Arizona Board of Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences & BIO5, University of Arizona Cancer Center, Skin Cancer Institute, Tucson, AZ (DSA); Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention; Centre for Cancer Prevention, Queen Mary University of London, Mile End Road, London, UK (JC); Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA (TWK); Moores Cancer Center (SML) and Department of Family Medicine and Public Health, Cancer Prevention and Control Program (CLR), UC San Diego, San Diego, CA (SML); Dermatology Research Laboratories, University of Wisconsin; Madison, WI (HM); Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Center for Cancer Prevention Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ (CSY).
Scott D RamseyBiological Chemistry, Public Health, and Epidemiology, Chao Family Comprehensive Cancer Center, School of Medicine - University of California, Irvine, Irvine, CA (FLMJr); Arizona Board of Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences & BIO5, University of Arizona Cancer Center, Skin Cancer Institute, Tucson, AZ (DSA); Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention; Centre for Cancer Prevention, Queen Mary University of London, Mile End Road, London, UK (JC); Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA (TWK); Moores Cancer Center (SML) and Department of Family Medicine and Public Health, Cancer Prevention and Control Program (CLR), UC San Diego, San Diego, CA (SML); Dermatology Research Laboratories, University of Wisconsin; Madison, WI (HM); Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Center for Cancer Prevention Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ (CSY).
Scott M LippmanBiological Chemistry, Public Health, and Epidemiology, Chao Family Comprehensive Cancer Center, School of Medicine - University of California, Irvine, Irvine, CA (FLMJr); Arizona Board of Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences & BIO5, University of Arizona Cancer Center, Skin Cancer Institute, Tucson, AZ (DSA); Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention; Centre for Cancer Prevention, Queen Mary University of London, Mile End Road, London, UK (JC); Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA (TWK); Moores Cancer Center (SML) and Department of Family Medicine and Public Health, Cancer Prevention and Control Program (CLR), UC San Diego, San Diego, CA (SML); Dermatology Research Laboratories, University of Wisconsin; Madison, WI (HM); Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Center for Cancer Prevention Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ (CSY).
David S AlbertsBiological Chemistry, Public Health, and Epidemiology, Chao Family Comprehensive Cancer Center, School of Medicine - University of California, Irvine, Irvine, CA (FLMJr); Arizona Board of Regents Professor of Medicine, Pharmacology, Public Health, Nutritional Sciences & BIO5, University of Arizona Cancer Center, Skin Cancer Institute, Tucson, AZ (DSA); Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention; Centre for Cancer Prevention, Queen Mary University of London, Mile End Road, London, UK (JC); Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA (TWK); Moores Cancer Center (SML) and Department of Family Medicine and Public Health, Cancer Prevention and Control Program (CLR), UC San Diego, San Diego, CA (SML); Dermatology Research Laboratories, University of Wisconsin; Madison, WI (HM); Hutchinson Institute for Cancer Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Center for Cancer Prevention Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ (CSY).
University of Arizona · USQueen Mary University of London · GBMadison Group (United States) · USUniversity of Arizona Cancer CenterUniversity of California, Irvine · USUniversity of Pittsburgh · US
Funding
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9MUniv.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9MTargeting Nrf2 for Cancer ChemopreventionR35CA197222 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KENSLER, THOMAS W · 2015 to 2021
$6.7MReducing Breast Cancer Recurrence with Weight Loss: A Vanguard TrialR01CA148791 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROCK, CHERYL L · 2010 to 2013
$4.9MTHYMIDYLATE SYNTHETASE AND RELATED ENZYMESR01CA014394 · NCI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI STROUD, ROBERT M · 1985 to 2001
$708kTHYMIDYLATE SYNTHETASE AND RELATED ENZYMESR37CA014394 · NCI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI SANTI, DANIEL V. · 1989 to 1997
–Cancer Research UK 16891Cancer Research UK A16891Cancer Research UK C569NCI NIH HHS 1U54CA14394NCI NIH HHS P01CA078447NCI NIH HHS P30 CA023100NCI NIH HHS P30CA 023100NCI NIH HHS P30CA-62203NCI NIH HHS R01CA 148791NCI NIH HHS R35 CA197222NCI NIH HHS R35CA 197222NIAMS NIH HHS 1R13AR068914091
Abstract
Approaches to reduce the global burden of cancer include two major strategies: screening and early detection and active preventive intervention. The latter is the topic of this Commentary and spans a broad range of activities. The genetic heterogeneity and complexity of advanced cancers strongly support the rationale for early interruption of the carcinogenic process and an enhanced focus on prevention as a priority strategy to reduce the burden of cancer; however, the focus of cancer prevention management should be on individuals at high risk and on primary localized disease in which screening and detection should also play a vital role. The timing and dose of (chemo-)preventive intervention also affects response. The intervention may be ineffective if the target population is very high risk or already presenting with preneoplastic lesions with cellular changes that cannot be reversed. The field needs to move beyond general concepts of carcinogenesis to targeted organ site prevention approaches in patients at high risk, as is currently being done for breast and colorectal cancers. Establishing the benefit of new cancer preventive interventions will take years and possibly decades, depending on the outcome being evaluated. We also propose that comparative effectiveness research designs and the value of information obtained from large-scale prevention studies are necessary in order for preventive interventions to become a routine part of cancer management.
Indexed as
Early Detection of CancerFeeding BehaviorRisk Reduction BehaviorAnimalsAnticarcinogenic AgentsChemopreventionClinical Trials as TopicComparative Effectiveness ResearchHumansMass ScreeningNeoplasmsNeoplasms, ExperimentalPrecision MedicinePrimary PreventionResearch DesignRisk AssessmentAnticarcinogenic Agents
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.